0000899243-23-020075.txt : 20231031 0000899243-23-020075.hdr.sgml : 20231031 20231031213907 ACCESSION NUMBER: 0000899243-23-020075 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231027 FILED AS OF DATE: 20231031 DATE AS OF CHANGE: 20231031 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ege David S. CENTRAL INDEX KEY: 0001829360 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37465 FILM NUMBER: 231366338 MAIL ADDRESS: STREET 1: C/O SERES THERAPEUTICS, INC. STREET 2: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Seres Therapeutics, Inc. CENTRAL INDEX KEY: 0001609809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274326290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617 945 9626 MAIL ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Seres Health, Inc. DATE OF NAME CHANGE: 20140603 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-10-27 0 0001609809 Seres Therapeutics, Inc. MCRB 0001829360 Ege David S. C/O SERES THERAPEUTICS, INC. 200 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 See Remarks 1 Common Stock 2023-10-27 4 M 0 11361 0.00 A 71057 D Common Stock 2023-10-30 4 S 0 4066 1.35 D 66991 D Restricted Stock Units 2023-04-27 4 A 0 22721 0.00 A Common Stock 22721 22721 D Restricted Stock Units 2023-10-27 4 M 0 11361 0.00 D Common Stock 11361 11360 D On February 3, 2023, the reporting person was granted an award of 22,721 RSUs, which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 11,361 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 11,360 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 17, 2023, solely with the intent to cover taxes in connection with the vesting of the RSUs. The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.3425 to $1.405, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. Executive Vice President and Chief Technology Officer /s/ Thomas J. DesRosier, attorney-in-fact for David S. Ege 2023-10-31